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not significantly different between the two treatment groups from baseline to end 
of treatment. However, there was a statistically significant improvement in Pain 
QLQ-C30 score from baseline to week 3 (OR= 3.14, p= 0.036) and week 6 (OR= 3.33, 
p= 0.034) in the metronomic arm compared with the cisplastin arm. ConClusions: 
Understanding the impact of different treatment options on changes in QoL over 
time can not only aid physicians in communication with patients but also assist 
in the design of interventions that focus on rehabilitation of patients with head 
and neck cancer.
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objeCtives: To monitor changes in health related quality of life (HRQoL) among 
advanced stage non small cell lung cancer (NSCLC) patients receiving oral gefi-
tinib. Methods: An observational study was conducted at the Tata Memorial 
Hospital, Mumbai, India, among stage-IV NSCLC patients who were > 18 years, had 
failed conventional chemotherapy, had EGFR mutation reports available, and were 
scheduled to receive oral gefitinib 250 mg OD treatment. Patients who met the 
inclusion criteria and agreed to participate in the study were recruited between 
January 1, 2010 and June 30, 2012. In addition to recording demographic and baseline 
clinical characteristics, patients were asked to rate their HRQoL using the European 
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC 
QLQ-LC13 questionnaires (Indian versions) at baseline and at every two months 
till the patient developed progressive disease or deteriorated in performance sta-
tus. Results: A total of 167 patients participated in the study. The mean age of 
study participants was 58.5 years (S.D.± 11.8). About 37.8% patients had a history 
of any kind of tobacco use. Significant improvements in overall quality of life were 
observed from baseline at week 16 (p= 0.001), week 24 (p= 0.02), and week 32 (p= 0.03). 
Furthermore, lung cancer symptom score (QLQ-LC-13) significantly decreased at 
week 8 (p= 0.019) and week 16 (p< < 0.01) as compared to baseline. Compared to 
baseline, pain in the arm and shoulder (QLQ-LC-13) decreased at week 8 (p= 0.008) 
and week 16 (p= 0.0025), as did pain in chest (QLQ-LC-13) at week 8 (p= 0.049) and 
week 16 (p= 0.003). ConClusions: Gefitinib has not only shown a favorable toxicity 
profile but it has also demonstrated significant improvements over time in overall 
QoL, as well as, on domains such a symptom relief and pain. Therefore, Gefitinib 
could be considered as a viable treatment option in patients with advanced NSCLC.
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objeCtives: Health-related quality of life (HRQoL) is essential in treatment deci-
sions for metastatic breast cancer (mBC), therefore, it’s important to understand 
the impact of treatment on patient-reported outcomes (PRO) in a real-world set-
ting. This study aims to characterize the impact of mBC and cancer treatments on 
HRQoL, treatment satisfaction and daily productivity from the patient perspec-
tive. Methods: This is a cross-sectional survey of 360 patients with mBC (US, 
n= 200; EU, n= 160). Post-menopausal women aged ≥ 50 years, with hormone receptor 
positive (HR+), HER2-negative (HER2-) mBC, currently using hormonal therapy (HT) 
or using chemotherapy (CT) for ≤ 1 year were recruited. The Functional Assessment 
of Cancer Therapy–Breast (FACT-B), Work Productivity and Activity Impairment, 
Cancer Treatment Satisfaction Questionnaire (CTSQ), patient-centric questions 
related to mBC, demographics, and adverse events (AEs) were assessed across CT 
and HT users. Multivariate analyses compared CT vs. HT with adjustments for 
demographics, comorbidities, and disease/treatment related measures. Results: 
Among the 360 patients, 53% (n= 191) reported CT and 47% (n= 169) reported HT 
use. Patient characteristics were generally similar between treatment cohorts with 
an average age of 58.3 years (SD= 6.3). HT users reported higher FACT-B scores (78.0 
vs. 70.1, p< 0.001), higher scores on the FACT-B subscales (physical, emotional and 
functional well-being, and breast cancer, p< 0.05 for all), greater satisfaction with 
treatment (subscale of the CTSQ; 74.1 vs. 67.2, p< 0.001), and better feelings about 
side-effects (subscale of the CTSQ; 48.2 vs. 41.6, p< 0.001). HT users reported less 
bother with treatment AEs (0-5 scale, 1.0 vs. 1.3, p< 0.001) and less activity impair-
ment compared with CT (52.6% vs. 60.8%, p< 0.001). ConClusions: Findings sug-
gest that HT is associated with better HRQoL, greater treatment satisfaction, less 
treatment related AEs, and less activity impairment compared with CT in 1st line 
mBC. These findings should be taken into consideration while making treatment 
decisions for HR+/HER2- mBC.
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objeCtives: The COMPLEMENT 1 trial demonstrated significantly better progres-
sion-free survival with ofatumumab combined with chlorambucil (O+CHL) [22.4 
months] versus chlorambucil alone (CHL) [13.1 months] in patients with chronic 
lymphocytic leukemia . The impact on health-related quality of life (HRQoL) was also 
assessed. Methods: 447 previously untreated patients were randomized to receive 
3-12 cycles of O+CHL or CHL. The European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and QLQ-CLL16 were administered at screening (base-
line), day 1 of cycles 4, 7, 10 and post-therapy. The pre-specified HRQoL outcomes 
were changes from baseline during and post therapy, and treatment differences in 
the two arms for Global Health Scale (GHS) of the QLQ-C30 and the Fatigue scale 
of the QLQ-CLL16. For treatment comparisons, mixed-model repeated measures 
(MMRM) analysis of covariance was used. Results: 428 patients completed at least 
one HRQoL assessment; with a median of 6 treatment cycles, cycle 10 had too few 
patients to analyze. For GHS, patients had improvements greater than the minimally 
important difference of 5 points for the CHL arm (Cycle 7) and for the O+CHL arm 
(Cycles 4 and 7). For the Fatigue scale, patients showed improvement from base-
line in both arms at Cycles 4 and 7. Most scales showed numerical improvements 
in both arms; exceptions were four scales in the CHL and two in the O+CHL arm. 
Post therapy, there were positive numerical changes from the last on-treatment 
visit in both arms for GHS and Fatigue scales. MMRM analysis showed no differ-
ences between treatment arms for GHS or Fatigue scales. ConClusions: Patients 
receiving either O+CHL or CHL experienced improvements in HRQoL during therapy. 
Off treatment, patients continued to maintain or increase the improvements. The 
addition of ofatumumab to chlorambucil did not negatively impact HRQoL and may 
improve certain aspects of patients’ HRQoL during and after treatment.
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objeCtives: Cancer is related to lower health-related quality of life (HRQoL). 
However, little evidence exists regarding the marginal decrease in HRQoL by the 
presence of comorbid anxiety and mood disorders (bipolar and depressive disorders) 
among cancer survivors based on U.S population-based research. The objective of 
the study was to determine whether comorbid anxiety and mood disorders were 
associated decreased HRQoL among cancer survivors. Methods: This cross-sec-
tional study used data from the 2011 Medical Expenditure Panel Surveys (MEPS). 
The independent variable was the presence of anxiety and/or mood disorders, and 
the dependent variable was HRQoL, which was measured using the SF-12 physical 
health composite scale (PCS) and mental health composite scale (MCS). Descriptive 
statistics, chi-square tests, and generalized linear models (GLM) were used for analy-
ses. Results: Among the estimated 17,987,639 cancer survivors, 9.4% had anxiety 
but not mood mood disorders, 11.4% had mood disorders but not anxiety, 3.8% 
had both anxiety and mood disorders, and 75.7% had neither anxiety nor mood 
disorders. The chi-square tests shows that the prevalence of anxiety and/or mood 
disorders was significantly different by age groups (p< 0.001), gender (p= 0.002), 
and perceived health status (p< 0.001), while it was not significantly different by 
race, insurance type, marital status, region, family income, and the presence of 
comorbidity. In the GLMs analyzing anxiety mood disorders separately, anxiety and 
mood disorders were both significantly associated with lower PCS scores (p= 0.002 
and p< 0.001) and MCS scores (both p< 0.001). After controlling for demographic 
and clinical factors, anxiety was not significantly associated with lower PCS scores 
(p= 0.235), but was associated with lower MCS scores (p= 0.005), and mood disorders 
were still significantly associated with both lower PCS (p= 0.006) and MCS (p< 0.001) 
scores. ConClusions: Both anxiety and mood disorders were independently asso-
ciated with lower HRQoL among cancer survivors, but when controlling for other 
factors, mood disorders showed no association with the PCS.
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objeCtives: Evaluate changes in health related quality of life (HRQoL) in patients 
with metastatic head and neck cancer randomized to receive either metronomic 
(methotrexate and celecoxib) or cisplatin chemotherapy. Methods: Patients older 
than 18 years, Karnofsky performance score of > 70 and diagnosed with metastatic, 
locally advanced inoperable or recurrent head and neck cancer not amenable to 
surgery or radiation were randomized (1:1) to receive of metronomic or 6 cycles of 
cisplatin chemotherapy. All patients were recruited from the Tata Memorial Hospital 
(TMH), Mumbai, India. In addition to demographic and baseline clinical character-
istics, patients were asked to rate their HRQoL using the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35 
questionnaires (Indian versions) at baseline and at the end of each chemo-cycle 
(every three weeks) till the end of study (week 18) or early termination. Results: 
Of the 110 patients screened, 87 agreed to participate in the study. Mean age of the 
study population was 47.5 years (S.D.± 10.04) for the metronomic group and 47.2 
years (S.D.± 9.89) for the cisplatin group. Oral cavity was the primary site of cancer 
(metronomic arm: 77.8%; cisplatin arm: 71.4%). About 57.8% and 45.2% patients 
had a history of tobacco use in both treatment arms. Overall quality of life was 
